Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Both companies are seeking to license their products as they try to stretch their dwindling cash.

AL002 failed across the board in a mid-stage study, and Alector has trimmed its workforce as it refocuses on its other two assets.

Analysts are hoping for a sizeable benefit on PFS when the full data emerge.

Recent data put Vir and Bluejay ahead of the pack, but it is hard to know exactly how well their products work.

But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.